Review of a 5-year experience with the radiostrontium bone scintiscan.

PubWeight™: 1.02‹?› | Rank: Top 15%

🔗 View Article (PMC 1518464)

Published in Calif Med on July 01, 1972

Authors

W C Gnekow, G L DeNardo, G J Poole, J P Kriss

Articles cited by this

Alkaline phosphatase. Ann Intern Med (1967) 1.54

The pathologic basis of the strontium bone scan. Studies following administration of strontium chloride Sr 85 and strontium nitrate Sr 85. JAMA (1968) 1.14

Detection of osseous metastases. Evaluation of bone scanning with strontium-85. Cancer (1967) 0.91

A critical analysis of strontium bone scanning for detection of metastatic cancer. Am J Roentgenol Radium Ther Nucl Med (1966) 0.90

Photoscanning of bone lesions utilizing strontium 85. Radiology (1961) 0.90

Strontium-85 scanning of suspected bone disease. Br Med J (1969) 0.89

Skeletal scintigraphy as an aid in practical roentgenographic diagnosis. Am J Roentgenol Radium Ther Nucl Med (1968) 0.89

Radiostrontium bone scanning in Hodgkin's disease. Cancer (1968) 0.86

Detection of bone lesions with the strontium-85 scintiscan. J Nucl Med (1966) 0.84

Scintiscanning in malignant lymphomatous involvement of bone. Arch Intern Med (1968) 0.84

AUTORADIOGRAPHIC LOCALIZATION OF STRONTIUM 85 IN OSTEOSARCOMAS. Acta Radiol Ther Phys Biol (1963) 0.81

Strontium 85 scanning of a "brown tumour" in a patient with parathyroid carcinoma. Br J Radiol (1969) 0.81

85Sr scintimetry in osteoarthritis of the knee. J Nucl Med (1969) 0.81

[Diagnostic value of strontium-85 for evaluation of the spread of a tumorous process in the bones]. Chir Narzadow Ruchu Ortop Pol (1968) 0.80

[Scintigraphy and profile measurement with 85Sr for the diagnosis of primary and secondary bone tumors]. Radiol Austriaca (1968) 0.80

Radioactive bone scans in carcinoma of the prostate. South Med J (1968) 0.80

Articles by these authors

(truncated to the top 100)

Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int (1985) 4.76

Prediction of myelotoxicity using semi-quantitative marrow image scores. J Nucl Med (1997) 1.94

Binding of thyroglobulin and thyroglobulin-antithyroglobulin immune complex to extraocular muscle membrane. Endocrinology (1974) 1.92

Appearance of Graves' disease on orbital computed tomography. J Comput Assist Tomogr (1979) 1.67

Supervoltage orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab (1973) 1.66

Prognostic factors in the radiotherapy of Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys (1990) 1.65

Clinical assessment of left ventricular regional contraction patterns and ejection fraction by high-resolution gated scintigraphy. J Nucl Med (1975) 1.48

The ventilatory lung scan in the diagnosis of pulmonary embolism. N Engl J Med (1970) 1.44

Survival time of circulating long-acting thyroid stimulator in neonatal thyrotoxicosis: implications for diagnosis and therapy of the disorder. Pediatrics (1965) 1.39

Reproducibility of thallium-201 myocardial imaging. Circulation (1977) 1.36

HL-A antigens as markers for disease susceptibility and autoimmunity in Graves' disease. J Clin Endocrinol Metab (1974) 1.33

Studies on the pathogenesis of the ophthalmopathy of Graves' disease. J Clin Endocrinol Metab (1967) 1.26

Copper-67-labeled monoclonal antibody Lym-1, a potential radiopharmaceutical for cancer therapy: labeling and biodistribution in RAJI tumored mice. J Nucl Med (1988) 1.17

Planar gamma camera imaging and quantitation of yttrium-90 bremsstrahlung. J Nucl Med (1994) 1.15

NanoFerrite particle based radioimmunonanoparticles: binding affinity and in vivo pharmacokinetics. Bioconjug Chem (2008) 1.11

Radioisotopic thyroidolymphography in patients with Graves' disease. J Clin Endocrinol Metab (1970) 1.11

A comparative study of copper-67 radiolabeling and kinetic stabilities of antibody-macrocycle chelate conjugates. Cancer (1994) 1.09

Potential use of amino acid cocktails to reduce renal tubular reabsorption of radioconjugates. J Nucl Med (1996) 1.08

Clinical experience with sensitive thyrotropin measurements: diagnostic and therapeutic implications. J Nucl Med (1985) 1.08

Pre-clinical evaluation and efficacy studies of a melanin-binding IgM antibody labeled with 188Re against experimental human metastatic melanoma in nude mice. Cancer Biol Ther (2008) 1.07

Screening for bone metastases. Are only scans necessary? JAMA (1975) 1.06

Effect of the extent of chelate substitution on the immunoreactivity and biodistribution of 2IT-BAT-Lym-1 immunoconjugates. Cancer Res (1995) 1.06

Measurements by competitive binding radioassay of serum anti-microsomal and anti-thyroglobulin antibodies in Graves' disease and other thyroid disorders. J Clin Endocrinol Metab (1971) 1.06

Studies on the pathogenesis of Graves' ophthalmopathy (with some related observations regarding therapy). Recent Prog Horm Res (1975) 1.05

Computed tomography in orbital pseudothumor (idiopathic orbital inflammation). Radiology (1976) 1.04

Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A (1997) 1.04

Scintigraphy in the diagnosis of osteonecrosis. Clin Orthop Relat Res (1978) 1.02

Direct dose confirmation of quantitative autoradiography with micro-TLD measurements for radioimmunotherapy. J Nucl Med (1988) 1.01

Apoptosis-related gene and protein expression in human lymphoma xenografts (Raji) after low dose rate radiation using 67Cu-2IT-BAT-Lym-1 radioimmunotherapy. Cancer Biother Radiopharm (2001) 1.01

Serum stability of 67Cu chelates: comparison with 111In and 57Co. Int J Rad Appl Instrum B (1986) 1.00

Transfer of copper from a chelated 67Cu-antibody conjugate to ceruloplasmin in lymphoma patients. Nucl Med Biol (1999) 0.99

Comparison of methods for acceleration of small intestinal radiographic examination. Radiology (1971) 0.98

Allogeneic cytolysis of reconstituted membrane vesicles. Proc Natl Acad Sci U S A (1979) 0.98

Radioisotopic angiocardiography: findings in congenital heart disease. J Nucl Med (1972) 0.98

Alterations in serum thyrotropin (TSH) and thyroid function following radiotherapy in patients with malignant lymphoma. J Clin Endocrinol Metab (1971) 0.97

Yttrium-90-labeled monoclonal antibody for therapy: labeling by a new macrocyclic bifunctional chelating agent. J Nucl Med (1990) 0.97

Scintigraphic imaging of a blind-ending ureteral duplication. J Nucl Med (1975) 0.96

Assessment of conventional criteria for the early diagnosis of thrombophlebitis with the 125I-fibrinogen uptake test. Radiology (1977) 0.96

Radioimmunotherapy: recent results and future directions. J Clin Oncol (1996) 0.96

Comparative serum stability of radiochelates for antibody radiopharmaceuticals. J Nucl Med (1987) 0.94

Blood flow in irradiated mouse sarcoma as determined by the clearance of xenon-133. Cancer Res (1972) 0.94

Interpolative background subtraction. J Nucl Med (1976) 0.94

Vascularity of the femoral head. Tc diphosphonate scintigraphy validated with tetracycline labeling. Clin Orthop Relat Res (1977) 0.94

Distribution and fate of synthetic lipid vesicles in the mouse: a combined radionuclide and spin label study. Proc Natl Acad Sci U S A (1974) 0.93

85 Sr bone scan in neoplastic disease. Semin Nucl Med (1972) 0.93

Quantitative bremsstrahlung imaging of yttrium-90 using a Wiener filter. Med Phys (1994) 0.92

Primary intracranial esthesioneuroblastoma, (olfactory neuroblastoma). J Neurosurg (1973) 0.92

The influence of lipid substitution on thyrotropin-receptor interactions in artificial vesicles. Endocrinology (1977) 0.91

Monoclonal antithyroglobulin antibodies derived from immunizations of mice with human eye muscle and thyroid membranes. J Clin Endocrinol Metab (1986) 0.91

In vivo distribution of vesicles loaded with radiopharmaceuticals: a study of different routes of administration. J Nucl Med (1975) 0.91

The 85-Sr scintiscan in bone disease. Ann Intern Med (1966) 0.91

Radioisotopic angiocardiography. Wide scope of applicability in diagnosis and evaluation of therapy in diseases of the heart and great vessels. Circulation (1971) 0.91

Radionuclide assessment of nitroglycerin influence on abnormal left ventricular segmental contraction in patients with coronary heart disease. Circulation (1976) 0.91

Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body. J Nucl Med (1999) 0.90

Graves' ophthalmopathy following external neck irradiation for nonthyroidal neoplastic disease. J Clin Endocrinol Metab (1973) 0.90

A clinical trial of radioimmunotherapy with 67Cu-2IT-BAT-Lym-1 for non-Hodgkin's lymphoma. J Nucl Med (1999) 0.90

Quantitative imaging of mouse L-6 monoclonal antibody in breast cancer patients to develop a therapeutic strategy. Int J Rad Appl Instrum B (1991) 0.90

Studies of an in vitro binding reaction between thyroid microsomes and long acting thyroid stimulator globulin (LATS). I. Development of solid-state competitive binding radioassay methods for measurement of antimicrosomal and antithyroglobuin antibodies. J Clin Endocrinol Metab (1970) 0.89

A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol (1996) 0.89

HL-A antigens in Japanese Patients with Graves' disease. Tissue Antigens (1975) 0.89

Computed tomography in Graves' ophthalmopathy. Radiology (1976) 0.88

Thyroglobulin-independent, cell-mediated cytotoxicity of human eye muscle cells in tissue culture by lymphocytes of a patient with Graves' ophthalmopathy. Life Sci (1983) 0.88

Anti-HLA-DR/anti-DOTA diabody construction in a modular gene design platform: bispecific antibodies for pretargeted radioimmunotherapy. Cancer Biother Radiopharm (2001) 0.88

Hepatic scintiangiographic patterns. Radiology (1974) 0.88

Sodium flux in myotonic muscular dystrophy. Am J Physiol (1968) 0.88

Unruptured aneurysm of the sinus of valsalva producing right ventricular outflow obstruction. Am J Med (1972) 0.88

Technetium-99m pyrophosphate myocardial uptake in patients with stable angina pectoris. Am J Cardiol (1977) 0.88

Treatment of B cell malignancies with 131I Lym-1 monoclonal antibodies. Int J Cancer Suppl (1988) 0.87

New approach to interpretation of technetium-99m pyrophosphate scintigraphy in detection of acute myocardial infarction: clinical assessment of diagnostic accuracy. Am J Cardiol (1977) 0.87

Cell-mediated lysis of lipid vesicles containing eye muscle protein: implications regarding pathogenesis of Graves ophthalmopathy. Proc Natl Acad Sci U S A (1979) 0.87

Critical evaluation of hepatic scintiangiography for neoplastic tumors of the liver. J Nucl Med (1975) 0.87

Treatment of orbital pseudotumor (idiopathic orbital inflammation) by radiation therapy. Int J Radiat Oncol Biol Phys (1980) 0.87

Origin and evolution of radioactive pulmonary emboli in man. Radiology (1968) 0.86

Inactivation of long-acting thyroid stimulator (LATS) by anti-kappa and anti-lambda antisera. J Clin Endocrinol Metab (1968) 0.85

Radiometric measurement of thyroglobulin-antithyroglobulin immune complex in human serum. J Clin Endocrinol Metab (1977) 0.85

L6 monoclonal antibody binds prostate cancer. Prostate (1998) 0.85

Neovascular targeting with cyclic RGD peptide (cRGDf-ACHA) to enhance delivery of radioimmunotherapy. Cancer Biother Radiopharm (2000) 0.85

Sounding board: On white coats and other matters. N Engl J Med (1975) 0.85

The biologic window for chimeric L6 radioimmunotherapy. Cancer (1994) 0.84

Detection of bone lesions with the strontium-85 scintiscan. J Nucl Med (1966) 0.84

Scintiscanning in malignant lymphomatous involvement of bone. Arch Intern Med (1968) 0.84

The long-acting thyroid stimulator and thyroid disease. Adv Intern Med (1970) 0.84

Immunoradiometric assay for serum thyroglobulin: semiquantitative measurement of thyroglobulin in antithyroglobulin-positive sera. J Clin Endocrinol Metab (1979) 0.83

Treatment of a patient with B cell lymphoma by I-131 LYM-1 monoclonal antibodies. Int J Biol Markers (1988) 0.83

Optimized conditions for chelation of yttrium-90-DOTA immunoconjugates. J Nucl Med (1998) 0.83

Radioimmunotherapy for breast cancer using escalating fractionated doses of 131I-labeled chimeric L6 antibody with peripheral blood progenitor cell transfusions. Cancer Res (1995) 0.83

The diagnosis of intracardiac metastasis of colon carcinoma by radioisotopic and roentgenographic studies. Am J Cardiol (1970) 0.83

Trials and tribulations: oncological antibody imaging comes to the fore. Semin Nucl Med (1997) 0.83

Prediction of radiation doses from therapy using tracer studies with iodine-131-labeled antibodies. J Nucl Med (1996) 0.83

Radioimmunotherapy with (111)In/(90)Y-2IT-BAD-m170 for metastatic prostate cancer. Clin Cancer Res (2001) 0.82

Cell-mediated immunity in severely head-injured patients: the role of suppressor lymphocytes and serum factors. J Neurosurg (1992) 0.82

Evaluation of the liver and spleen in Hodgkin's disease. I. The value of hepatic scintigraphy. Am J Med (1972) 0.82

Helper and suppressor activities of lymphocyte subsets on antithyroglobulin production in vitro. J Clin Endocrinol Metab (1985) 0.82

Lymphoma-selective antibody Lym-1 recognizes a discontinuous epitope on the light chain of HLA-DR10. Cancer Immunol Immunother (1996) 0.82

Radioimmunotherapy for breast cancer using indium-111/yttrium-90 BrE-3: results of a phase I clinical trial. J Nucl Med (1997) 0.81

67Cu-2IT-BAT-Lym-1 pharmacokinetics, radiation dosimetry, toxicity and tumor regression in patients with lymphoma. J Nucl Med (1999) 0.81

Immunochemical aspects of monoclonal antibodies important for radiopharmaceutical development. Int J Rad Appl Instrum B (1986) 0.81

Comparison of radiolabeled bleomycins and gallium citrate in tumor-bearing mice. J Nucl Med (1977) 0.81

Tc99m labelled toluidine blue O for liver scintillography. Int J Appl Radiat Isot (1968) 0.81

Combined modality radioimmunotherapy with Taxol and 90Y-Lym-1 for Raji lymphoma xenografts. Cancer Biother Radiopharm (1998) 0.81